Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Feasibility and acceptability of virtual reality use during intrauterine device procedures: a London-based health service evaluation.

BMJ sexual & reproductive health·2026
Same author

Increased synaptic turnover in injured cortical axons: exploring the role of SARM1 ablation.

Frontiers in synaptic neuroscience·2026
Same author

Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease.

Nature aging·2026
Same author

Alzheimer's Imaging Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Erratum to "Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers" [The Journal of Prevention of Alzheimer's Disease volume 12 (2025) 100302].

The journal of prevention of Alzheimer's disease·2025
Same author

A Multisite Implementation of the Comfort Ability Program Telehealth Intervention for Pediatric Chronic Pain: Insights From Patients, Caregivers, and Providers.

The Clinical journal of pain·2025
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Cardiovascular-kidney-metabolic syndrome stage modifies the efficacy of intensive blood pressure control on cognitive outcomes: A post hoc analysis of SPRINT MIND.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evidence of APOE4-related brain vulnerabilities in verbal memory systems in midlife women.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Changes in DNA methylation-based aging predicts brain damage and dementia and reflects life-course cardiovascular risk.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Elimination of tau tangles and soluble aggregates with the small molecule ACI-16664 prevents neurodegeneration in vivo.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

薬物開発

Melanie Shulman1, Shuang Wu1, Jing Xie1

  • 1Biogen, Cambridge, MA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
まとめ
この要約は機械生成です。

この第2相試験では、早期アルツハイマー病（AD）を対象に、アンチセンスオリゴヌクレオチドであるBIIB080を検討します。この試験は、軽度の認知障害または認知症の患者におけるタウ病理を減少させ、疾患進行を遅らせる可能性を目的としています。

キーワード:
アルツハイマー病タウ病理BIIB080アンチセンスオリゴヌクレオチド第2相試験臨床試験神経科学薬理学

さらに関連する動画

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

関連する実験動画

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学分野:

  • 神経科学
  • 薬理学
  • 臨床試験

背景:

  • アルツハイマー病（AD）の治療には、アミロイド療法があるにもかかわらず、未だ満たされていないニーズがあります。
  • タウ病理はADの臨床的障害と強く相関しています。
  • アンチセンスオリゴヌクレオチドであるBIIB080は、タウmRNAを標的としてタウタンパク質の産生を減少させます。

研究 の 目的:

  • 早期ADにおけるBIIB080の有効性、安全性、および忍容性を評価します。
  • タウ病理を減少させる上でのBIIB080の用量反応を評価します。
  • 認知低下およびADバイオマーカーに対するBIIB080の影響を調査します。

主な方法:

  • 第2相、無作為化、二重盲検、プラセボ対照試験（CELIA、NCT05399888）。
  • 早期AD（MCIまたは軽度認知症）、50〜80歳の参加者416名。
  • 76週間にわたる髄注BIIB080またはプラセボ。主要評価項目：76週時点でのCDR-SBの変化。

主要な成果:

  • 第2相CELIA試験の登録は完了しました。
  • 予備的なベースライン特性は、他の早期AD試験と比較して同等です。
  • 結果の完全な特性評価は発表される予定です。

結論:

  • 進行中のCELIA試験は、早期ADにおけるプラセボに対するBIIB080の有効性と安全性を決定します。
  • BIIB080は、以前の研究でタウバイオマーカーに対して有望な効果を示しています。
  • この試験は、アルツハイマー病に対するタウ標的療法の進歩にとって極めて重要です。